Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Khalid Islam | M | 67 |
Arpida AG
 Arpida AG BiotechnologyHealth Technology Arpida AG develops and discovers drugs for microbial resistance. The company's products include intravenous iclaprim, and antibiotics. The antibiotics provides resistance towards the methicillin-resistant Staphylococcus aureus (MRSA). The company also discovers an oral formulation of iclaprim. The company was founded by Dr. Dieter Gillessen, Bernhard Erni and Dr. Ivan Kompis in July 1997 and is headquartered in Reinach, Switzerland. | 9 years |
| André L. Lamotte | M | 75 |
Arpida AG
Arpida AG BiotechnologyHealth Technology Arpida AG develops and discovers drugs for microbial resistance. The company's products include intravenous iclaprim, and antibiotics. The antibiotics provides resistance towards the methicillin-resistant Staphylococcus aureus (MRSA). The company also discovers an oral formulation of iclaprim. The company was founded by Dr. Dieter Gillessen, Bernhard Erni and Dr. Ivan Kompis in July 1997 and is headquartered in Reinach, Switzerland. | 12 years |
| Harry Welten | M | 59 |
Arpida AG
Arpida AG BiotechnologyHealth Technology Arpida AG develops and discovers drugs for microbial resistance. The company's products include intravenous iclaprim, and antibiotics. The antibiotics provides resistance towards the methicillin-resistant Staphylococcus aureus (MRSA). The company also discovers an oral formulation of iclaprim. The company was founded by Dr. Dieter Gillessen, Bernhard Erni and Dr. Ivan Kompis in July 1997 and is headquartered in Reinach, Switzerland. | 8 years |
| Elmar Schnee | M | 65 |
Arpida AG
Arpida AG BiotechnologyHealth Technology Arpida AG develops and discovers drugs for microbial resistance. The company's products include intravenous iclaprim, and antibiotics. The antibiotics provides resistance towards the methicillin-resistant Staphylococcus aureus (MRSA). The company also discovers an oral formulation of iclaprim. The company was founded by Dr. Dieter Gillessen, Bernhard Erni and Dr. Ivan Kompis in July 1997 and is headquartered in Reinach, Switzerland. | - |
| Michel Lucien Pettigrew | M | 71 |
Arpida AG
Arpida AG BiotechnologyHealth Technology Arpida AG develops and discovers drugs for microbial resistance. The company's products include intravenous iclaprim, and antibiotics. The antibiotics provides resistance towards the methicillin-resistant Staphylococcus aureus (MRSA). The company also discovers an oral formulation of iclaprim. The company was founded by Dr. Dieter Gillessen, Bernhard Erni and Dr. Ivan Kompis in July 1997 and is headquartered in Reinach, Switzerland. | - |
| Jürgen Raths | M | 68 |
Arpida AG
Arpida AG BiotechnologyHealth Technology Arpida AG develops and discovers drugs for microbial resistance. The company's products include intravenous iclaprim, and antibiotics. The antibiotics provides resistance towards the methicillin-resistant Staphylococcus aureus (MRSA). The company also discovers an oral formulation of iclaprim. The company was founded by Dr. Dieter Gillessen, Bernhard Erni and Dr. Ivan Kompis in July 1997 and is headquartered in Reinach, Switzerland. | 1 years |
| Hans Fünfschilling | M | - |
Arpida AG
Arpida AG BiotechnologyHealth Technology Arpida AG develops and discovers drugs for microbial resistance. The company's products include intravenous iclaprim, and antibiotics. The antibiotics provides resistance towards the methicillin-resistant Staphylococcus aureus (MRSA). The company also discovers an oral formulation of iclaprim. The company was founded by Dr. Dieter Gillessen, Bernhard Erni and Dr. Ivan Kompis in July 1997 and is headquartered in Reinach, Switzerland. | - |
| Jon Bondebjerg | M | - |
Arpida AG
Arpida AG BiotechnologyHealth Technology Arpida AG develops and discovers drugs for microbial resistance. The company's products include intravenous iclaprim, and antibiotics. The antibiotics provides resistance towards the methicillin-resistant Staphylococcus aureus (MRSA). The company also discovers an oral formulation of iclaprim. The company was founded by Dr. Dieter Gillessen, Bernhard Erni and Dr. Ivan Kompis in July 1997 and is headquartered in Reinach, Switzerland. | 3 years |
| Matthias Staehelin | M | - |
Arpida AG
Arpida AG BiotechnologyHealth Technology Arpida AG develops and discovers drugs for microbial resistance. The company's products include intravenous iclaprim, and antibiotics. The antibiotics provides resistance towards the methicillin-resistant Staphylococcus aureus (MRSA). The company also discovers an oral formulation of iclaprim. The company was founded by Dr. Dieter Gillessen, Bernhard Erni and Dr. Ivan Kompis in July 1997 and is headquartered in Reinach, Switzerland. | - |
| Dieter Gillessen | M | - |
Arpida AG
Arpida AG BiotechnologyHealth Technology Arpida AG develops and discovers drugs for microbial resistance. The company's products include intravenous iclaprim, and antibiotics. The antibiotics provides resistance towards the methicillin-resistant Staphylococcus aureus (MRSA). The company also discovers an oral formulation of iclaprim. The company was founded by Dr. Dieter Gillessen, Bernhard Erni and Dr. Ivan Kompis in July 1997 and is headquartered in Reinach, Switzerland. | 12 years |
| Ivan Kompis | M | - |
Arpida AG
Arpida AG BiotechnologyHealth Technology Arpida AG develops and discovers drugs for microbial resistance. The company's products include intravenous iclaprim, and antibiotics. The antibiotics provides resistance towards the methicillin-resistant Staphylococcus aureus (MRSA). The company also discovers an oral formulation of iclaprim. The company was founded by Dr. Dieter Gillessen, Bernhard Erni and Dr. Ivan Kompis in July 1997 and is headquartered in Reinach, Switzerland. | 12 years |
| Paul Verbraeken | M | - |
Arpida AG
Arpida AG BiotechnologyHealth Technology Arpida AG develops and discovers drugs for microbial resistance. The company's products include intravenous iclaprim, and antibiotics. The antibiotics provides resistance towards the methicillin-resistant Staphylococcus aureus (MRSA). The company also discovers an oral formulation of iclaprim. The company was founded by Dr. Dieter Gillessen, Bernhard Erni and Dr. Ivan Kompis in July 1997 and is headquartered in Reinach, Switzerland. | - |
Statistics
| Country | Connections | % of total |
|---|---|---|
| Switzerland | 12 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Bernhard Erni
- Personal Network
